Intended for healthcare professionals


First treatment for rare heart condition to be available in England

BMJ 2024; 385 doi: (Published 13 May 2024) Cite this as: BMJ 2024;385:q1082
  1. Jacqui Wise
  1. Kent

An innovative drug, tafamidis, will be available from 13 May for NHS patients in England with the rare heart condition transthyretin amyloidosis cardiomyopathy (ATTR-CM).

Patients with ATTR-CM have a build-up of protein in the heart which often results in heart failure and can be fatal. Symptoms include shortness of breath, palpitations and abnormal heart rhythms, fatigue, fainting, and chest pain. Previous treatment …

View Full Text

Log in

Log in through your institution


* For online subscription